MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY
The present application relates to oligonucleotides (e.g., antisense oligonucleotides such as gapmers) designed to target DMPK RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease. In some...
Gespeichert in:
Hauptverfasser: | , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; fre |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | NAJIM, John DESJARDINS, Cody PICARIELLO, Tyler SUBRAMANIAN, Romesh QUINN, Brendan ZANOTTI, Stefano WEEDEN, Timothy QATANANI, Mohammed |
description | The present application relates to oligonucleotides (e.g., antisense oligonucleotides such as gapmers) designed to target DMPK RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DMPK.
La présente demande concerne des oligonucléotides (par exemple, des oligonucléotides antisens tels que des gapmères) conçus pour cibler des ARN DMPK et des complexes de ciblage pour administrer les oligonucléotides à des cellules (par exemple, des cellules musculaires) et leurs utilisations, en particulier des utilisations se rapportant au traitement de maladies. Selon certains modes de réalisation, l'agent de ciblage musculaire se lie de manière spécifique à un récepteur de surface cellulaire d'internalisation sur des cellules musculaires. Dans certains modes de réalisation, la charge utile moléculaire inhibe l'expression ou l'activité de DMPK. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2023283620A8</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2023283620A8</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2023283620A83</originalsourceid><addsrcrecordid>eNrjZPD2DQ129nFVCHEMcncN8fRzV3D29w3wcY1wDVZw9HNRCA0GMkI8XINc_d0U3PyDFEKCXB3B6nwj_UP8_TydFVwig0OC_AM8InkYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXy4v5GBkbGRhbGZkYGjhTFxqgB3Dy8T</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY</title><source>esp@cenet</source><creator>NAJIM, John ; DESJARDINS, Cody ; PICARIELLO, Tyler ; SUBRAMANIAN, Romesh ; QUINN, Brendan ; ZANOTTI, Stefano ; WEEDEN, Timothy ; QATANANI, Mohammed</creator><creatorcontrib>NAJIM, John ; DESJARDINS, Cody ; PICARIELLO, Tyler ; SUBRAMANIAN, Romesh ; QUINN, Brendan ; ZANOTTI, Stefano ; WEEDEN, Timothy ; QATANANI, Mohammed</creatorcontrib><description>The present application relates to oligonucleotides (e.g., antisense oligonucleotides such as gapmers) designed to target DMPK RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DMPK.
La présente demande concerne des oligonucléotides (par exemple, des oligonucléotides antisens tels que des gapmères) conçus pour cibler des ARN DMPK et des complexes de ciblage pour administrer les oligonucléotides à des cellules (par exemple, des cellules musculaires) et leurs utilisations, en particulier des utilisations se rapportant au traitement de maladies. Selon certains modes de réalisation, l'agent de ciblage musculaire se lie de manière spécifique à un récepteur de surface cellulaire d'internalisation sur des cellules musculaires. Dans certains modes de réalisation, la charge utile moléculaire inhibe l'expression ou l'activité de DMPK.</description><language>eng ; fre</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231102&DB=EPODOC&CC=WO&NR=2023283620A8$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231102&DB=EPODOC&CC=WO&NR=2023283620A8$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>NAJIM, John</creatorcontrib><creatorcontrib>DESJARDINS, Cody</creatorcontrib><creatorcontrib>PICARIELLO, Tyler</creatorcontrib><creatorcontrib>SUBRAMANIAN, Romesh</creatorcontrib><creatorcontrib>QUINN, Brendan</creatorcontrib><creatorcontrib>ZANOTTI, Stefano</creatorcontrib><creatorcontrib>WEEDEN, Timothy</creatorcontrib><creatorcontrib>QATANANI, Mohammed</creatorcontrib><title>MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY</title><description>The present application relates to oligonucleotides (e.g., antisense oligonucleotides such as gapmers) designed to target DMPK RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DMPK.
La présente demande concerne des oligonucléotides (par exemple, des oligonucléotides antisens tels que des gapmères) conçus pour cibler des ARN DMPK et des complexes de ciblage pour administrer les oligonucléotides à des cellules (par exemple, des cellules musculaires) et leurs utilisations, en particulier des utilisations se rapportant au traitement de maladies. Selon certains modes de réalisation, l'agent de ciblage musculaire se lie de manière spécifique à un récepteur de surface cellulaire d'internalisation sur des cellules musculaires. Dans certains modes de réalisation, la charge utile moléculaire inhibe l'expression ou l'activité de DMPK.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPD2DQ129nFVCHEMcncN8fRzV3D29w3wcY1wDVZw9HNRCA0GMkI8XINc_d0U3PyDFEKCXB3B6nwj_UP8_TydFVwig0OC_AM8InkYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXy4v5GBkbGRhbGZkYGjhTFxqgB3Dy8T</recordid><startdate>20231102</startdate><enddate>20231102</enddate><creator>NAJIM, John</creator><creator>DESJARDINS, Cody</creator><creator>PICARIELLO, Tyler</creator><creator>SUBRAMANIAN, Romesh</creator><creator>QUINN, Brendan</creator><creator>ZANOTTI, Stefano</creator><creator>WEEDEN, Timothy</creator><creator>QATANANI, Mohammed</creator><scope>EVB</scope></search><sort><creationdate>20231102</creationdate><title>MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY</title><author>NAJIM, John ; DESJARDINS, Cody ; PICARIELLO, Tyler ; SUBRAMANIAN, Romesh ; QUINN, Brendan ; ZANOTTI, Stefano ; WEEDEN, Timothy ; QATANANI, Mohammed</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2023283620A83</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2023</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>NAJIM, John</creatorcontrib><creatorcontrib>DESJARDINS, Cody</creatorcontrib><creatorcontrib>PICARIELLO, Tyler</creatorcontrib><creatorcontrib>SUBRAMANIAN, Romesh</creatorcontrib><creatorcontrib>QUINN, Brendan</creatorcontrib><creatorcontrib>ZANOTTI, Stefano</creatorcontrib><creatorcontrib>WEEDEN, Timothy</creatorcontrib><creatorcontrib>QATANANI, Mohammed</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>NAJIM, John</au><au>DESJARDINS, Cody</au><au>PICARIELLO, Tyler</au><au>SUBRAMANIAN, Romesh</au><au>QUINN, Brendan</au><au>ZANOTTI, Stefano</au><au>WEEDEN, Timothy</au><au>QATANANI, Mohammed</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY</title><date>2023-11-02</date><risdate>2023</risdate><abstract>The present application relates to oligonucleotides (e.g., antisense oligonucleotides such as gapmers) designed to target DMPK RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DMPK.
La présente demande concerne des oligonucléotides (par exemple, des oligonucléotides antisens tels que des gapmères) conçus pour cibler des ARN DMPK et des complexes de ciblage pour administrer les oligonucléotides à des cellules (par exemple, des cellules musculaires) et leurs utilisations, en particulier des utilisations se rapportant au traitement de maladies. Selon certains modes de réalisation, l'agent de ciblage musculaire se lie de manière spécifique à un récepteur de surface cellulaire d'internalisation sur des cellules musculaires. Dans certains modes de réalisation, la charge utile moléculaire inhibe l'expression ou l'activité de DMPK.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng ; fre |
recordid | cdi_epo_espacenet_WO2023283620A8 |
source | esp@cenet |
subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
title | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T04%3A38%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=NAJIM,%20John&rft.date=2023-11-02&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2023283620A8%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |